The widely-prescribed drug Ozempic, along with others in its class, may offer substantial benefits for individuals living with bipolar disorder, according to new research.
A study conducted by Griffith University in Australia examined data from approximately 15,000 individuals over a 15-year period and found that those taking semaglutide, the active ingredient in Ozempic and Wegovy, experienced a 21% lower risk of psychiatric hospitalization. This finding suggests the drug could play a role in managing the extreme mood swings characteristic of the condition.
Bipolar disorder affects nearly 7 million adults in the U.S., leading to episodes of mania and depression that can require hospitalization. These episodes can range from suicidal ideation during depressive phases to psychosis and dangerous impulsivity during manic periods.
Professor Mark Taylor, who led the study, highlighted the significance of these findings, stating that they add to emerging evidence suggesting GLP-1 receptor agonists might have therapeutic effects beyond their established uses for diabetes and obesity. He indicated that these drugs could represent a promising area for future bipolar disorder research.
Researchers hypothesize that semaglutide may protect the brain by reducing inflammation, cellular stress, and other biological processes implicated in bipolar disorder, thereby contributing to improved mood stability. The drug's known impact on neurotransmitters like dopamine, which influences mood and reward pathways, might also contribute to this effect.
It is important to note that the study specifically linked semaglutide to the reduced risk of psychiatric hospitalization. Other GLP-1 drugs, such as liraglutide (Victoza, Saxenda) and dulaglutide (Trulicity), did not show the same association in this research.
Previous studies have also pointed to potential mental health benefits of GLP-1 medications. Research has indicated an "antidepressant effect" associated with their use, independent of weight loss. Furthermore, a study involving obese teenagers found that semaglutide led to a 33% reduction in suicidal ideation or attempts. Some anecdotal reports also suggest improvements in attention, focus, and impulse control among individuals with ADHD who take these medications, though scientists are still investigating a direct causal link for these specific symptoms.